Literature DB >> 3496595

Induction and regulation of mRNA encoding 26-kDa protein in human cell lines treated with recombinant human tumor necrosis factor.

P Defilippi, P Poupart, J Tavernier, W Fiers, J Content.   

Abstract

A 26-kDa protein, originally described in human fibroblasts superinduced for interferon beta (IFN-beta) production, and termed IFN-beta 2 by other investigators, is induced by cycloheximide and by a 22-kDa, interleukin 1 (IL-1)-related factor. Although the structure and sequence of the corresponding gene show nonhomology with the IFN-beta gene, the gene is identical to that of B-cell stimulatory factor 2, a human interleukin, and displays a very potent growth and differentiation factor activity for B lymphocytes. In this work we show that IL-1 beta and tumor necrosis factor (TNF) strongly induce the 26-kDa protein in FS-4 fibroblasts and in some transformed cell lines. Addition of cycloheximide to recombinant (r)IL-1 beta and rTNF further enhances the level of 26-kDa-protein mRNA. We determined the kinetics of induction and the amounts of rTNF and rIL-1 beta required for optimal induction of this mRNA in FS-4 cells and in HeLa H21 cells and found that rIL-1 beta is a more efficient inducer of 26-kDa protein mRNA than is TNF. By analyzing the inducibility of the 26-kDa protein gene by rTNF and rIL-1 beta in a series of transformed cell lines that differ in their sensitivity to the cytotoxic action of TNF, we report a direct correlation between the 26-kDa protein mRNA expression and the resistance of these cells to the cytotoxic effect of TNF.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496595      PMCID: PMC305129          DOI: 10.1073/pnas.84.13.4557

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines.

Authors:  L Fransen; J Van der Heyden; R Ruysschaert; W Fiers
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

2.  Type beta transforming growth factor: a bifunctional regulator of cellular growth.

Authors:  A B Roberts; M A Anzano; L M Wakefield; N S Roche; D F Stern; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

3.  Expression of the 2-5A system during the cell cycle.

Authors:  V Wells; L Mallucci
Journal:  Exp Cell Res       Date:  1985-07       Impact factor: 3.905

4.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.

Authors:  D Pennica; G E Nedwin; J S Hayflick; P H Seeburg; R Derynck; M A Palladino; W J Kohr; B B Aggarwal; D V Goeddel
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

5.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

6.  Induction of a 26-kDa-protein mRNA in human cells treated with an interleukin-1-related, leukocyte-derived factor.

Authors:  J Content; L De Wit; P Poupart; G Opdenakker; J Van Damme; A Billiau
Journal:  Eur J Biochem       Date:  1985-10-15

7.  Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1.

Authors:  J Van Damme; M De Ley; G Opdenakker; A Billiau; P De Somer; J Van Beeumen
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

8.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

9.  Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts.

Authors:  G Haegeman; J Content; G Volckaert; R Derynck; J Tavernier; W Fiers
Journal:  Eur J Biochem       Date:  1986-09-15

10.  Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines.

Authors:  A Zilberstein; R Ruggieri; J H Korn; M Revel
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

View more
  27 in total

Review 1.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

Review 2.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

3.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6.

Authors:  H Loppnow; P Libby
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

5.  Beta interferon subtype 1 induction by tumor necrosis factor.

Authors:  H Jacobsen; J Mestan; S Mittnacht; C W Dieffenbach
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

6.  Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells.

Authors:  C P Chiu; C Moulds; R L Coffman; D Rennick; F Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

7.  Insulinotropic and anti-inflammatory effects of rosiglitazone in experimental autoimmune diabetes.

Authors:  Wageh M Awara; Alaa E el-Sisi; Mohamed el-Refaei; Mona M el-Naa; Karima el-Desoky
Journal:  Rev Diabet Stud       Date:  2005-11-10

8.  Sensitivity to tumour necrosis factor-mediated cytolysis is unrelated to manganous superoxide dismutase messenger RNA levels among transformed mouse fibroblasts.

Authors:  J M Boss; S M Laster; L R Gooding
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

9.  Common expression of a tumor necrosis factor resistance mechanism among gynecological malignancies.

Authors:  C B Powell; D G Mutch; L S Massad; M S Kao; J L Collins
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

10.  Elevated serum interleukin-6 levels in patients with acute hepatitis.

Authors:  Y Sun; K Tokushige; E Isono; K Yamauchi; H Obata
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.